N/A N=166 Randomized Health Services Research

SPREAD-NET: PRactices Enabling Adapting and Disseminating in the Safety NET

Diabetes Mellitus · Cardiovascular Disease

Bottom Line

View on ClinicalTrials.gov: NCT02325531 ↗

Enrolled (actual)

166

Serious AEs

—

Results posted

Dec 2022

Primary outcome: Primary: Rate Ratio of the Percent of the Clinics' Patients "Indicated" for Statin With a Guideline-appropriate Prescription for Statins — 1.09; 1.11; 1.06; 1.04 Rate ratio

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Low support (Other); Medium support (Other); High support (Other); Comparison (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Kaiser Permanente
Primary completion: Aug 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Rate Ratio of the Percent of the Clinics' Patients "Indicated" for Statin With a Guideline-appropriate Prescription for Statins	1.09; 1.11; 1.06; 1.04	—
PRIMARY Rate Ratio of the Percent of the Clinics' Patients "Indicated" for ACE/ARB With Guideline-appropriate Prescription for ACE/ARBs	0.95; 0.99; 0.99; 0.95	—
SECONDARY Identify Clinic Characteristics Associated With the Support Strategies' Effectiveness (e.g. Decision-making Structures, Leadership Support, Team Processes I Characteristics, Readiness and Capacity for Change).	—	—
SECONDARY Rate Ratio of the Change in the Percent of the Clinic's 'Indicated' Patients With Correct Intensity Statin Prescribing	1.24; 1.35; 1.11; 1.17	—

Summary

The investigators propose to compare the effectiveness of 3 strategies (low, medium, high intensity) at supporting CHCs' implementation of the ALL Initiative (an intervention shown to reduce patients' cardiovascular disease (CVD) event risk), through a cluster-randomized trial.

Eligibility Criteria

Inclusion Criteria

Convenience sample, all patients with Diabetes Mellitus from 30 community health clinics (CHCs) that are members of OCHIN, Inc.

Exclusion Criteria

Patients without diagnosed DM

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02325531). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.